Previous 10 | Next 10 |
Top-line data from the Phase 3 RAISE study expected in early 2021 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gM...
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease in which the nerve cells in the spinal cord and brain slowly die, leading to impairment of voluntary muscle movement. Patients lose the ability to eat, breathe, walk, and talk ...
Multi-center platform trial sponsored by the Healey Center will simultaneously assess multiple drug regimens Zilucoplan selected by leading experts in ALS as one of the first therapeutic candidates to be tested Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection o...
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to zilucoplan for the treatment of myasthenia gravis. Ra Pharma is developing zilucoplan, a self-administered macrocyclic peptide inhibitor of complement c...
Marks the second compound from Ra’s Extreme Diversity™ platform to enter clinical trials Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.S. ...
Ra Pharmaceuticals (NASDAQ: RARX ): Q2 GAAP EPS of -$0.52 misses by $0.03 . More news on: Ra Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Initiation of single, pivotal, 12-week, Phase 3 gMG clinical trial on track for the second half of 2019 Initiation of multi-center, Phase 2 IMNM clinical trial on track for the second half of 2019 Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the s...
Achillion Pharmaceuticals ( ACHN ) had achieved a massive surge in stock price recently. It all started when it had reported positive data from a phase 1 study using its drug ACH-5228. This data was early, but investors were optimistic based on the initial findings of the impressive sustai...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Ra Pharmaceuticals, Inc. (Nasdaq: RARX) (“Ra Pharma”) today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.50 per share, including 600,000 shares sold pursuant to the underwriters’ exerci...
News, Short Squeeze, Breakout and More Instantly...
Ra Pharmaceuticals Inc. Company Name:
RARX Stock Symbol:
NASDAQ Market:
Ra Pharmaceuticals Inc. Website:
Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13 th Annual Rare Disease Day ® , an awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people l...
Enrollment ongoing in Phase 3 clinical trial of zilucoplan in gMG, with top-line results expected in early 2021 First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020 IND cleared by FDA for the HEALEY ALS Plat...
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its Board of Direc...